Itraconazole in the Treatment of Coccidioidomycosis

Díaz, Manuel Concha; Puente, Roberto Zarrabeitia; Hoyos, Leticia; Cruz, Samuel Gonçalves da

doi:10.1378/chest.100.3.682

Cited by 35 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trials using newer azole compounds (ketoconazole, fluconazole and itraconazole) are in progress. These offer hope for patients who are either intolerant of amphotericin-B, or who require long-term suppressive treatment [13][14][15].…”

Section: Discussionmentioning

confidence: 99%

Disseminated coccidioidomycosis in an American soldier in Europe

Libow

Lum

Jackson

et al. 1995

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Disseminated coccidioidomycosis in an American soldier in Europe

Libow

Lum

Jackson

et al. 1995

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The three oral azole antifungals introduced in the 1980s and 1990s were ketoconazole, itraconazole, and fluconazole. Each has been the subject of multiple clinical trials as therapy for chronic pulmonary and extrapulmonary coccidioidomycosis including coccidioidal meningitis 44–62 . Many of these studies were carried out by a single, multicenter collaboration known as the Mycoses Study Group, and most were phase II, open‐label studies of individual drugs; none were randomized studies in comparison to amphotericin B.…”

Section: Advent Of Orally Absorbed Azole Antifungal Drugsmentioning

confidence: 99%

“…Each has been the subject of multiple clinical trials as therapy for chronic pulmonary and extrapulmonary coccidioidomycosis including coccidioidal meningitis. [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] Many of these studies were carried out by a single, multicenter collaboration known as the Mycoses Study Group, and most were phase II, open-label studies of individual drugs; none were randomized studies in comparison to amphotericin B. However, one study by this group compared fluconazole and itraconazole in a prospective, randomized, double-blinded protocol.…”

Section: Advent Of Orally Absorbed Azole Antifungal Drugsmentioning

confidence: 99%

Coccidioidomycosis: Changing Perceptions and Creating Opportunities for Its Control

Galgiani

2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The perceptions of coccidioidomycosis as a medical problem has undergone sequential and dramatic metamorphoses since its first description more than a century ago. First thought to be rare and lethal, coccidioidomycosis was subsequently found to be common and often mild. During World War II, its overall impact upon large populations came sharply into focus and the consequences for public health became clearer. Early treatments had significant limitations and toxicities, and therefore treatment of coccidioidomycosis was reserved for only the sickest patients. Since then, safer oral therapies have become commonplace. Despite their availability, there has been no investigation of their use in the less severe and much more common early infections. Even newer drugs such as nikkomycin Z, which might actually cure infections, until very recently have had trouble finding a sponsor to move it through clinical trials. Perceptions once formed by the understanding of coccidioidomycosis as a medical problem now appear to hinder the future study of newer therapeutic opportunities. It is suggested in this review that it is time to revisit and possibly change these perceptions if we are to improve our care of patients.

show abstract

“…Amphotericin B seems to provide a faster clinical response; however, no clinical trials have directly compared these two classes of drugs. Research has shown that fluconazole and itraconazole are effective and well tolerated in the treatment of chronic pulmonary coccidioidomycosis and nonmeningeal disseminated coccidioidomycosis [32,33]. In a study comparing oral fluconazole, 400 mg daily, with itraconazole, 200 mg twice daily, in the treatment of progressive, nonmeningeal coccidioidomycosis, neither drug showed superior efficacy, although there was a trend toward slightly greater benefit with itraconazole [34••].…”

Section: Diagnosismentioning

confidence: 99%

Coccidioidomycosis pulmonary infection

Lin

Hamill

2001

Curr Infect Dis Rep

View full text Add to dashboard Cite

Disease caused by Coccidioides immitis has increased in frequency in recent years because of marked population shifts into highly endemic areas, as well as perturbations of the environment caused by construction, agricultural, and natural activities. Because disease may occur in persons in locations outside of the endemic regions, practitioners must be aware of the possibility of infection in those who may have traveled or resided in areas of risk. Recently, advances in laboratory methods have facilitated diagnosis of coccidioidomycosis, and information about therapies that are easier to administer has become available. Challenges in the management of this infection still remain, particularly with regard to more reliable antifungal drugs and protective vaccines.

show abstract

Itraconazole in the Treatment of Coccidioidomycosis

Cited by 35 publications

References 13 publications

Disseminated coccidioidomycosis in an American soldier in Europe

Disseminated coccidioidomycosis in an American soldier in Europe

Coccidioidomycosis: Changing Perceptions and Creating Opportunities for Its Control

Coccidioidomycosis pulmonary infection

Contact Info

Product

Resources

About